Streetwise Expert Interviews


ROTH Capital's Debjit Chattopadhyay: Marriage of Diagnostics to New Therapies Breeds Biotech Winners

pillsblack82Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of ROTH Capital Partners recommends that biotech investors consider these trends when looking at portfolio options in the healthcare sector. A medical researcher turned biotech analyst, Chattopadhyay highlights several companies with unique diagnostic and therapeutic technologies in this interview with The Life Sciences Report. (7/24/14) More >


Read more Streetwise Interviews. . .

including Tempering Insane Optimism with Due Diligence: Alan Leong on Niche Biotech Prospects (7/17/14) More >

Newsletter Briefs

"Watch out for NEO; it is significantly undervalued given the opportunities that lie ahead." (7/24/14) NeoGenomics Laboratories - The Life Sciences Report interview with Debjit Chattopadhyay More >

"Shiseido's investment in a collaboration with RP is a form of validation for the company." (7/17/14) RepliCel Life Sciences Inc. - The Life Sciences Report interview with Alan Leong More >

"MSLP's transformation is not yet in the price of the stock." (7/8/14) MusclePharm Corp. - Paulo Santos, Seeking Alpha More >

"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >

"THLD initiated a Phase 2 trial with TH-302 in NSCLC." (7/8/14) Threshold Pharmaceuticals Inc. - Tony Schwartz, Seeking Alpha More >

"International sales continue to be a focus for MSLP and a reason for further bullishness." (6/27/14) MusclePharm Corp. - Chris Katje, Seeking Alpha More >

"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >

"We believe BLU has a higher probability of success in its current Phase 3 Kiacta study." (6/12/14) BELLUS Health Inc. - The Life Sciences Report interview with Brian Bloom More >

Expert Analysis

"CTH is set to begin Phase 2 clinical studies for APL-130277." (7/21/14) Cynapsus Therapeutics Inc. - Daniel Pearlstein, M Partners More >

"The RNN story can now be viewed as an emerging opportunity." (7/18/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We are encouraged by NEO's volume growth of 40% in Q2/14." (7/18/14) NeoGenomics Laboratories - Amanda Murphy, William Blair More >

"The CTH-105 study will be initiated under CTH's IND application." (7/17/14) Cynapsus Therapeutics Inc. - Leonard Zehr, BioTuesdays More >

"INO has initiated preparatory activities for a possible Phase 3 study." (7/15/14) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group More >

"Its current cash position should take ATNM through at least mid-2015." (7/14/14) Actinium Pharmaceuticals Inc. - Edward White, Laidlaw & Company More >

"THLD has initiated a large Phase 2 trial investigating TH-302." (7/14/14) Threshold Pharmaceuticals Inc. - Philippa Gardner, Edison Investment Research More >

"KOOL is an undervalued player with significant long-term upside." (7/8/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. More >